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After hematopoietic stem cell transplantation (HSCT), successful engraftment and immune recovery is
necessary to protect the patient from relapse and infection. Many studies highlight the importance of con-
ventional ab T cell recovery after HSCT, but the impact of gd T cell recovery has not been well described. Here,
we investigate the recovery of gd T cells in 102 pediatric patients with acute leukemia in ﬁrst clinical
remission who underwent allogeneic HSCT at St. Jude Children’s Research Hospital from 1996 to 2011. Mean
patient age was 10.5  5.9 years (range, .6 to 25.2), and mean survivor follow-up was 2.7  1.8 years (range,
.12 to 6.0). Diagnoses included 59% patients with acute lymphoblastic leukemia and 41% patients with acute
myelogenous leukemia. Multivariate analysis demonstrated signiﬁcant impact of the maximum number of
CD3þ, CD4þ, and CD8þ T cells and donor source on the gd T cell recovery (P < .0001, P < .0001, P < .0001, and
P < .004, respectively). Univariate and multivariate models found the number of gd T cells after HSCT to be
associated with infections (P ¼ .026 and P ¼ .02, respectively). We found the probability of infections for
patients with an elevated number of gd T cells was signiﬁcantly lower compared with patients with low or
normal gd T cells after HSCT (18% versus 54%; P ¼ .025). Bacterial infections were not observed in patients
with elevated gd T cells. Finally, event-free survival was signiﬁcantly higher in patients with enhanced gd T
cell reconstitution compared with patients with low/normal gd T cell reconstitution after HSCT (91% versus
55%; P ¼ .04). Thus, gd T cells may play an important role in immune reconstitution after HSCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION phosphorylated microbial metabolites and lipids, nonclas-
Delayed immune reconstitution after hematopoietic stem
cell transplantation (HSCT) increases transplant-related
mortality due to relapse and infection. Prompt recovery of
T cells, speciﬁcally CD4þ T cells, has been shown to signiﬁ-
cantly decrease the risk of infections [1]. Most studies focus
on ab T cells, and the impact of gd T cell reconstitution in
infections after HSCT has not been well investigated [2,3].
Unlike conventional ab T cells, gd T cells are described as
“bridging” adaptive and innate immunity. The speciﬁc re-
ceptors on gd T cells detect unconventional antigens such asedgments on page 135.
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ty for Blood and Marrow Transplantation.sical MHC class I molecules, and unprocessed proteins [4-6].
gd T cells are concentrated within epithelial and mucosal
surfaces to maintain epidermal integrity of the skin and in-
testinal epithelium [7-10]. Studies suggest that tissue-
speciﬁc antigens are recognized by gd T cells resulting in
immune responses protecting these potential sites of path-
ogen entry into the body [11,12]. Furthermore, increasing
evidence indicates gd T cells also possess potent innate
antitumor activity [13-15]. A report by Gertner-Dardenne
et al. [14] found that gd T cells were effective in targeting
acute myelogenous leukemia by the perforin and granzyme
pathway in vitro and in the mouse model. Lamb et al. [16]
reported the increased frequency of gd T cells in disease-
free survivors after T celledepleted, partially mismatched,
related donor HSCT for leukemia. Godder et al. [17] showed
that adults with acute leukemia with higher numbers of gd T
R. Perko et al. / Biol Blood Marrow Transplant 21 (2015) 130e136 131cells after HSCT had a signiﬁcant increase in leukemia-free
survival compared with patients with low or normal gd T
cells. Thus, in the partially mismatched, related donor HSCT,
the beneﬁcial associations between gd T cells and outcome
have been reported after HSCT [2,16,17].
Reconstitution of gd T cell repertoire diversity after allo-
geneic HSCT suggests that peripheral expansion of mature T
cells in the graft is 1 of themain pathway of gd Tcell recovery
in adults [18]. The recognition of gd T cells as a non-
alloreactive lymphocyte with potential anti-infectious and
antitumor properties has led to the use of gd T cells in
immunotherapy [19-21]. Currently, the ab T celledepletion
method to engineer a HSC graft that retains monocytes,
dendritic cells, natural killer (NK) cells, and gdþ T lympho-
cytes are used in the hope that it might improve the outcome
of patients undergoing of HSCT [22,23].
Here we report the ﬁrst detailed study of gd T cell
reconstitution after HSCT in pediatric patients. Because gd T
cells are known to have protective roles during various types
of infections [9], we evaluated infections as well as outcomes.
We found that gd T cell recovery during the ﬁrst year after
HSCT correlated with a reduced incidence of infection.
Furthermore, an increased number of gd T cells correlated
with a greater event-free survival (EFS) in the ﬁrst year after
HSCT. Further prospective studies evaluating larger numbers
of patients will be needed to determine a stronger correla-




Data were collected retrospectively on 102 consecutive patients with
acute leukemia in ﬁrst clinical remission (CR) who underwent an HSCT from
2006 to 2011 at St. Jude Children’s Research Hospital. All patients and/or
their parents or guardians provided written informed consent for their
participation, and all research was conducted under institutional review
boardeapproved protocols. Patients were excluded if they had secondary
leukemia or had undergone previous HSCT. The preparative regimen, graft
source/manipulation, and graft-versus-host disease (GVHD) prophylaxis is
detailed in Supplementary Table 1.
Patients undergoing matched unrelated donor (MUD) or matched
related donor (MRD) HSCT received a preparative regimen of cyclophos-
phamide with mesna (120 mg/kg), total body irradiation (12 Gy), and
antithymocyte globulin (ATG). Patients undergoing MUD or MRD HSCT with
a nonetotal body irradiation regimen received a preparative regimen of
targeted busulfan, cyclophosphamide (200 mg/kg), and ATG. Patients un-
dergoing an umbilical cord blood HSCT received a preparative regimen of
ﬂudarabine (75 mg/m2), cyclophosphamide (120 mg/kg), and total body
irradiation (1320 cGy). Patients undergoing a haploidentical (HAPLO)-HSCT
received a preparative regimen with thiotepa (10 mg/kg), melphalan
(120 mg/m2), and ﬂudarabine (200 mg/m2) or clofarabine (200 to 250 mg/
m2). Haploidentical patients received an ex vivo T celledepleted graft using
the CliniMACS system (Miltenyi Biotec Inc., Cambridge, MA) with a T cell
dose less than or equal to 1.0  105 CD3þ cells/kg.
Evaluation
Successful engraftment was deﬁned as the ﬁrst of 3 consecutive days
with an absolute neutrophil count of at least 500 cells/mL. Graft failure was
deﬁned as the absence of engraftment 42 days after HSCT. Relapse was
deﬁned as the presence of the patient’s initial diagnosis of leukemia in the
peripheral blood or bone marrow after reaching CR after HSCT. EFS was
deﬁned as any death, graft failure, or disease relapse after HSCT. GVHD was
deﬁned, diagnosed, and staged based on National Institutes of Health
consensus criteria. Patients were surveyed weekly with galactomannan
assay and viral PCR as previously described [24]. Additionally, cultures for
suspected pathogens were obtained when clinically indicated. Diagnosis of
infection was deﬁned when a positive culture or PCR for a pathogen was
found in association with a clinical illness.
Statistical Analysis
A Cox proportional hazard model was performed stepwise using back-
ward selection to determine variables with signiﬁcant relationship to OS.Univariate and multivariate logistic regression analyses were performed to
identify variables associated with infections. A generalized linear model was
performed to determine variables with a signiﬁcant relationship to the
number of gd T cells as a continuous or grouped variable. For the continuous
variable analysis, covariates were evaluated with time being ﬁxed. For the
grouped variables, patients with gd T cells greater than 1 standard deviation
above the mean value of gd T cells in the cohort on 2 consecutive lab draws
within the ﬁrst year after HSCT were grouped as “elevated.” The remainder
of the patients were grouped as “low or normal “ in gd T cell numbers.
Themeanvaluewas determined fromthedistribution ofgdTcell number
in the entire patient cohort before day 365  20. Using this discrimination,
we applied Fisher’s exact test to evaluate differences between groups in
gender, disease diagnosis, disease state, survival, relapse, GVHD, types of
donors, infection, and type of infections seen in patients. TheWilcoxon rank
sum testwas used to evaluate for differences between the 2 groups in patient
age and days to engraftment within the ﬁrst 100 days and to determine the
relationship of chronic GVHD to their gd T cell count at the time of diagnosis.
The Kruskal-Wallis rank sum test was used to evaluate the relationship of
clinical stage of acute GVHD to gd T cell numbers. The cumulative incidences
of acute and chronic GVHD after HSCT, relapse, and infection for the 2 groups
were estimated and compared as described by Prentice et al. [25] and Gray
et al. [26]. OS and EFS for the 2 patient groups were estimated according to
the Kaplan-Meier method [27] and were compared using the log-rank test.
OS end point was death, and EFS end points were death, relapse, or graft
failure after HSCT. All statistical analyses were performed with SAS software
version 9.2 (SAS, Cary, NC) and Prism v5.0b (GraphPad, La Jolla, CA).
RESULTS
Patients
From 2006 to 2011, gd T cell data on 102 patients (57%
males and 43% females) with acute leukemia in ﬁrst CR who
underwent an allogeneic HSCTat St. Jude Children’s Research
Hospital were evaluated retrospectively. Mean patient age
was 10.5  5.9 years (range, .6 to 25.2), and mean survivor
follow-up was 2.7  1.8 years (range, .12 to 6.0). Diagnoses
included 59% patients with acute lymphoblastic leukemia
and 41% patients with acute myelogenous leukemia. Patients
received MUD (41%), MRD (23%), haploidentical donor (31%),
or umbilical cord blood (5%) (Supplementary Table 1).
Variables Associated with gd T Cell Reconstitution after
HSCT
First, we evaluated the effect of various patient charac-
teristics and the associationwith gd Tcell reconstitution after
HSCT. Speciﬁcally, donor, age, gender, diagnosis, and GVHD
prophylaxis, GVHD, immune reconstitution, infection,
relapse, and survival were evaluated. Using univariate and
multivariate analysis, we found a signiﬁcant impact of donor
source on the gd T cell recovery (P ¼ .005 and P ¼ .006,
respectively; Table 1). Similarly, we found the number of
CD3þ, CD4þ, and CD8þ T cells to be signiﬁcantly associated
with gd T cell recovery using both univariate (P < .001,
P < .001, and P ¼ .01, respectively) and multivariate analyses
(P < .001, P < .001, and P < .001, respectively). Because gd T
cells are a subset of CD3þ T cells, we anticipated the positive
correlation of gd T cells and total CD3þ T cells after HSCT
(estimate¼ .4). However, themaximumnumber of CD4þ and
CD8þ T cells were inversely associated with gd Tcell recovery
in the multivariate model (estimate ¼ e.3 and e.4).
gd T Cells Are Inversely Correlated with the Incidence of
Infection after HSCT
Many studies have documented that poor T cell recovery
after HSCT is linked to infectious complications [4]. However,
the impact of gd T cell recovery on the incidence of infection
after HSCT in pediatric patients has not been well described.
Research has shown that gd T cells play a role in pathogen
clearance [28]; thus, we used a logistic regression model to
estimate the probability of developing an infection based on
Table 1
Univariate and Multivariate Analysis of Patient Characteristics and Associ-
ation with gd T Cells after HSCT
Univariate Analysis






MRD .071 .003 .025 .118
Cord .051 .194 .128 .026
Haplo .031 .138 .010 .073
Age .002 .148 .005 .001
Gender Female vs. male .024 .199 .013 .061
Diagnosis ALL vs. AML .003 .862 .034 .041
GVHD Prophylaxis CSA and MMF .010 .758 .075 .055
MTX and FK .004 .845 .035 .043
Acute GVHD Yes vs. no .020 .293 .018 .058
Chronic GVHD Yes vs. no .043 .122 .012 .098
Immune recovery CD3 .035 <.001* .020 .050
CD4 .096 <.001* .057 .136
CD8 .026 .011* .006 .046
NK .050 .048* .001 .100
CD19 .006 .679 .022 .033
Infection Yes vs. no .044 .018* .008 .080
Infection groups .097
None .034 .128 e.010 .078
Bacterial .018 .493 .070 .034
Fungal .059 .530 .246 .127
Viral .000
Relapse Yes vs. no .027 .245 .019 .074
Survival Yes vs. no .054 .005* .017 .091
Multivariate Analysis
Effect Category Estimate P Lower Upper
Donor .006*
Cord .03 .19 .09 .02
Haplo .025 .13 .008 .05
MRD .053 .004 .01 .08
MUD 0
Infection Yes .001 .406 .04 .01
Immune recovery CD3 .415 <.0001* .282 .548
CD4 .343 <.0001* .482 .205
CD8 .395 <.0001* .526 .264
NK .024 .238 .016 .065
CI indicates conﬁdence interval; ALL, acute lymphoblastic leukemia; AML,
acute myelogenous leukemia; CSA, cyclosporine A; MMF, mycophenolate
mofetil; MTX, methotrexate; FK, tacrolimus; MUD, matched unrelated
donor; MRD, matched related donor; Cord, cord blood donor; Haplo, hap-
loidentical donor; GVHD, graft-versus-host disease.
* Indicate statistical signiﬁcance observed.
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CD4, CD8, gd), B, and NK cells as continuous variables. Uni-
variate and multivariate analyses found the number of gd T
cells after HSCT to be associated with infections (P¼ .026 and
P ¼ .02, respectively). However, infection became not sta-
tistically signiﬁcant when expanding the analysis to evaluate
the effect of various donor sources and immune component.
Subanalysis of patients undergoing MRD/MUD and haplo-/
cord HSCTare provided in Supplementary Tables 2 through 9.
Although similar variables impacted gd T cells and the risks
for infections, the number of patients in each subgroup was
too small for analysis to reach statistical signiﬁcance. How-
ever, in the combined cohort analysis, the data demonstrate a
signiﬁcant association between the incidence of infections
and the number of gd T cells after HSCT.
Next, we evaluated the risk of infections to the number of
gd T cells as a grouped variable, as previously described by
Godder et al. [17]. During the ﬁrst year after HSCT, 11% of
patients had at least 2 consecutive measurements greater
than 1 standard deviation above the mean gd T cell numbers
(150 cells/mL). The remaining patients (89%) had low/normal gd T cell numbers (<150 cells/mL). The groups were
similar with respect to age, sex, disease, and donor source
(P ¼ .34, P ¼ 1, P ¼ 1, and P ¼ .07, respectively; Table 2). The
patients with elevated gd T cells had only viral infections (2/2
events), whereas the low/normal gd group had viral, bacte-
rial, and/or fungal infections (Figure 1A). Using a logistic
regression model, we found the cumulative incidence of
infection was signiﬁcantly lower for patients with an
elevated number of gd T cells compared with patients with
low/normal gd T cells after HSCT (.53 versus .18%; P ¼ .02)
(Figure 1B). In summary, the incidence of infection after
HSCT was signiﬁcantly higher in the low/normal gd T cell
group compared with the elevated group.
In addition, information regarding the percent of lym-
phocytes and number of CD3, ab, and gd Tcells over timewas
evaluated in patients with either low/normal or high gd T
cells (Supplementary Figure 1). Although there was a sig-
niﬁcant difference in the percent of gd T cells between the
low/normal and high gd group from day 56 (2.3% versus
3.5%; P ¼ .02), we found no signiﬁcant difference in the
percentage of ab T cells or CD3 T cells. Similar comparisons
were made with the total number of CD3, ab, and gd T cells
between the 2 groups. The total number of CD3 and ab T cells
was signiﬁcantly different between the low/normal and
elevated gd T cell groups early after HSCT at day 28 (P ¼ .051
and P¼ .01, respectively) but was not signiﬁcantly different at
later time points. Furthermore, the total number of CD3 and
ab T cells were not signiﬁcantly lower in the high gd group
compared with the low gd group, suggesting that lympho-
penia was not the signiﬁcant driving force for gd T cell
expansion. Finally, the potential effect of the lymphopenia
due to OKT3 and ATG were evaluated by determining the
number of patients in the elevated group who received OKT3
(2 or 18%) or ATG (2 or 18%). Most patients (63%) in the
elevated gd group did not receive ATG or OKT3.
Incidence of Engraftment, Relapse, GVHD, and Survival
Because infections and survival may be related to
engraftment, GVHD, or relapse, we determined if there was a
signiﬁcant association between gd T cell reconstitution and
these factors. No signiﬁcant differences were seen in the
incidence of engraftment or median time to engraftment in
the elevated group compared with the low/normal group
(19.0  6.1 and 18.2  7.5 days, respectively; P ¼ .8). The
overall median donor chimerism was 99.5% (range, 64.2% to
100%), whereas 99.5% of patients had low/normal gd T cells
(range, 62.1% to 100%) and 99.6% had elevated gd T cells
(range, 90.6% to 100%). There was no correlation between
chimerism and the low/normal or elevated gd T cell groups
(P ¼ .93). The disease-free survival between the patients in
the elevated gd T cell group compared with patients in the
low/normal gd T cell group was not signiﬁcantly different at
1 year (91% versus 79%; P ¼ .6) or 5 years (91% versus 74%;
P ¼ .25) after HSCT (Figure 2A). The median time to relapse
for the patients in the low/normal group was 177  185 days
(range, 23 to 746), and the relapse event occurring in the
elevated group was on day 365. The EFS in patients with an
elevated number of gd T cells compared with those who
recovered with low/normal gd cells was signiﬁcantly higher
(91% versus 55%; P ¼ .04) (Figure 2B).
Thirty-six deaths occurred in the cohort, due to recurrent
disease (21), multiorgan failure (5), infection (4), pulmonary
hemorrhage (3), hepatic failure (2), or veno-oclusive disease
(1). We determined whether gd T cell reconstitution had a
signiﬁcant effect on OS using a Cox proportional hazards
Table 2
Patient Characteristics and Distribution in the Low/Normal vs. High gd T Cell Group
Variable Category Overall (N ¼ 102) Low/Normal gd (n ¼ 91) High gd (n ¼ 11) P
Donor .147
MRD 22 (21.6%) 17 (18.7%) 5 (45.5%)
MUD 42 (41.2%) 40 (44.0%) 2 (18.2%)
Haplo 32 (31.4%) 28 (30.8%) 4 (36.4%)
UCB 6 (5.9%) 6 (6.6%) 0 (.0%)
Age .340
Mean  SD 10.5  5.91 10.7  5.96 9.0  5.60
Median (range) 10.5 (.6-25.2) 10.6 (.6-25.2) 10.2 (.6-16.3)
Gender 1.000
Female 44 (43.1%) 39 (42.9%) 5 (45.5%)
Male 58 (56.9%) 52 (57.1%) 6 (54.5%)
Diagnosis 1.000
ALL 60 (58.8%) 53 (58.2%) 7 (63.6%)
AML 42 (41.2%) 38 (41.8%) 4 (36.4%)
Acute GVHD .891
Grades I-II 28 (27.5%) 26 (28.6%) 2 (18.2%)
Grades III-IV 12 (11.8%) 11 (12.1%) 1 (9.1%)
No 62 (60.8%) 54 (59.3%) 8 (72.7%)
Chronic GVHD .351
No 89 (87.3%) 78 (85.7%) 11 (100.0%)
Yes 13 (12.7%) 13 (14.3%) 0 (.0%)
Chimerism .93
Mean  SD 97.6  5.34 97.6  5.57 98.3  2.99
Median (range) 99.5 (64.2-100) 99.5 (64.2-100) 99.6 (90.6-100)
Relapse .687
No 82 (80.4%) 72 (79.1%) 10 (90.9%)
Yes 20 (19.6%) 19 (20.9%) 1 (9.1%)
Survival .07
Alive 66 (64.7%) 56 (61.5%) 10 (90.9%)
Dead 36 (35.3%) 35 (38.5%) 1 (9.1%)
Infection .02
Yes 51 (50.0%) 49 (53.8%) 2 (18.2%) .08
No 51 (50.0%) 42 (46.2%) 9 (81.8%)
Bacterial infection .06
Yes 24 (23.5%) 24 (26.4%) 0 (.0%) .24
No 78 (76.5%) 67 (73.6%) 11 (100.0%)
Viral infection .7
Yes 26 (25.5%) 24 (26.4%) 2 (18.2%) 1.0
No 76 (74.5%) 67 (73.6%) 9 (81.8%)
Fungal infection 1.00
Yes 1 (1.0%) 1 (1.1%) 1.0
No 101 (99.0%) 90 (98.9%) 11 (100.0%)
GVHD prophylaxis (0-2 agents) 1.000
No 9 (8.8%) 8 (8.8%) 1 (9.1%)
Yes 93 (91.2%) 83 (91.2%) 10 (90.9%)
GVHD prophylaxis (3 agents) 1.000
No 35 (34.3%) 31 (34.1%) 4 (36.4%)
Yes 67 (65.7%) 60 (65.9%) 7 (63.6%)
GVHD treatment (steroids  third agent) 1.000
No 85 (83.3%) 76 (83.5%) 9 (81.8%)
Yes 17 (16.7%) 15 (16.5%) 2 (18.2%)
CD3 <.001*
Mean  SD 1.3  1.12 1.2  1.04 2.4  1.17
Median (range) 1.0 (.0-5.2) .8 (.0-5.2) 2.4 (1.0-4.9)
gd <.001*
Mean  SD .1  .09 .1  .05 .3  .09
Median (range) .1 (.0-.6) .1 (.0-.2) .3 (.2-.6)
CD4 .010*
Mean  SD .5  .43 .5  .38 .9  .61
Median (range) .4 (.0-2.0) .4 (.0-1.6) .8 (.1-2.0)
CD8 .001*
Mean  SD .8  .91 .7  .89 1.4  .89
Median (range) .5 (.0-4.4) .5 (.0-4.4) .8 (.6-3.2)
NK .639
Mean  SD .4  .37 .4  .28 .6  .78
Median (range) .4 (.0-2.9) .3 (.0-1.5) .4 (.1-2.9)
CD19 .078
Mean  SD .4  .68 .3  .69 .5  .58
Median (range) .2 (.0w5.5) .1 (.0-5.5) .3 (.1-1.9)
UCB indicates umbilical cord blood; SD, standard deviation.
P values for infections were adjusted for multiple comparisons by the Bonferroni method.
* Indicate statistical signiﬁcance observed between the low/normal vs. high gd T cell groups.
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Figure 2. Survival estimates for patients in low/normal and high gd T cell
group. The Kaplan-Meier estimates for (A) disease-free survival, (B) EFS, and
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Figure 1. Reconstitution of gd T cells and risk for infection. Infection was
deﬁned as a positive culture or PCR for a pathogen in association with a clinical
illness. Patients were surveyed weekly with galactomannan assay and PCR for
cytomegalovirus, Epstein-Barr virus, and adenovirus as previously described
[24]. Additional cultures for suspected pathogens were obtained when clini-
cally indicated. (A) Each point represents a patient and the documented
maximum gd T cell value in the ﬁrst year after HSCT. The mean value of gd for
patients with no documented infections (x) is compared with the mean value
of gd for patients with documented infections (O). Infections are further
depicted as bacterial, viral, or fungal infections. Error bar represents SEM. (B)
The cumulative incidence (CI) of infection is shown for patients in the low/
normal (- -) or high (d) gd T cell group.
R. Perko et al. / Biol Blood Marrow Transplant 21 (2015) 130e136134model (Supplementary Table 8). In a multivariate analysis
using the number of gd T cells as a continuous variable, we
found the number of gd T cells along with CD3þ and CD4þ T
cells had a signiﬁcant relationship with OS, (P ¼ .02, P < .001,
and P¼ .02, respectively) (Table 3). Of the 36 deaths, 35 (97%)
occurred in patients with low/normal gd T cells and 1 (3%)
occurred in the group with elevated gd T cells. The patient in
the elevated group died from relapse at 365 days after HSCT.
Using the Kaplan-Meier method, OS rates between the 2
groups were 91% versus 61% (P ¼ .06) (Figure 2C).
DISCUSSION
Early after HSCT, relapse and infections continue to be
major complications that signiﬁcantly impact survival.
Studies to improve immune reconstitution have heavily
focused on conventional T cells [1,29,30]. Studies have re-
ported the increased frequency of gd T cells in disease-free
survivors after T celledepleted, partially mismatched,
related donor HSCT for leukemia and suggested the beneﬁ-
cial association [16]. Godder et al. [17] showed that adultswith acute leukemia with higher numbers of gd T cells after
HSCT had a signiﬁcant increase in leukemia-free survival
compared with patients with low or normal gd T cells.
There is growing evidence of the beneﬁcial associations
between gd T cells and outcome of adults who undergo a
partially mismatched, related donor HSCT [2,16,17]. This
study is the ﬁrst to suggest that early gd T cell reconstitution
after HSCT decreases the risk of infection and impacts sur-
vival in pediatric patients who underwent MRD, MUD, and
haplo-HSCT. We initially determined whether patient char-
acteristics of gender, age, disease, preparative regimen,
GVHD prophylaxis, and donor source were associated with
gd T cell reconstitution. Compared with MUD, patients who
Table 3
Patient Characteristic and Association with Elevated gd T Cells after HSCT (Logistic Model)
Variable Category Estimate P Odds Ratio (95% CI)
Donor .256 d
Cord d d
Haplo 3.169 .981 >999.9 (<0.001; >999.9)
MRD 3.891 .976 >999.9 (<0.001; >999.9)
MUD 2.119 .987 >999.9 (<0.001; >999.9)
Age .048 .381 .953 (.856, 1.061)
Gender Male vs. female .052 .870 .900 (.256, 3.164)
Diagnosis AML vs. ALL .113 .732 .797 (.218, 2.916)
GVHD Prophylaxis CSA and MMF .019 .973 .963 (.109, 8.519)
MTX and FK .050 .880 .904 (.246, 3.327)
ATG  OKT3 .059 .887 1.126 (.221, 5.742)
Acute GVHD Yes vs. no .4878 .144 1.629 (.847, 3.131)
Chronic GVHD Yes vs. no 5.668 .958 >999.9 (<0.001; >999.9)
Relapse Yes vs. no .485 .369 .379 (.046, 3.147)
Survival Yes vs. no .916 .087 .160 (.020, 1.305)
Infection Yes vs. no .829 .041* .190 (.039, .931)
Infection groups .718 d
Bacterial d
Fungal 4.641 .983 1.000 (.000, 2E246)
None 5.114 .944 17,235 (.000, 33E52)
Viral 4.169 .954 6703 (.000, 13E52)
Immune CD3 .729 .003* 2.073 (1.288, 3.335)
recovery CD4 2.067 .003* 7.897 (2.007, 31.08)
CD 8 .562 .033* 1.755 (1.048, 2.939)
CD19 .256 .474 1.292 (.641, 2.604)
NK .988 .134 2.684 (.736, 9.785)
Due to small sample size of donor subgroups, chronic GVHD and infection sub groups, the odds ratios (95% CI) are not reported.
* Indicates statistical signiﬁcance at 0.05 level.
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ence in the recovery of gd T cells after HSCT. The impact of
graft source on immune reconstitution after HSCT has been
well reported, and the number of gd T cells present in the
graft will most likely play a role in immune recovery [1,2].
One limitation of this study was the gd T cell content of the
graft was not available, restricting the investigation of how
graft source impacts gd T cell reconstitution after HSCT.
Currents studies are underway to provide detailed informa-
tion regarding the infused graft product.
Here, we report the effect of gd T cell recovery after HSCT
by evaluating patients undergoing their ﬁrst HSCT with
similar diseases (acute leukemia) and disease status (ﬁrst
CR). Furthermore, gd T cells were evaluated as a continuous
variable to correlate the effect on infections and survival.
Thereafter, we identiﬁed the patients with elevated gd T cells
and conﬁrmed our ﬁndings that these patients had
decreased infections and increased survival. Because gd T
cells are a subset of CD3þ T cells, the direct correlation with
total number of CD3þ T cell recovery and gd T cells was
anticipated. It has been presumed that gd T cell recovery
would parallel CD4þ and CD8þ T cell recovery. On the con-
trary, recovery of gd T cells was inversely associated with the
number of CD4þ and CD8þ Tcells after HSCT. This may be due
to peripheral proliferation of gd T cells during severely
lymphopenic periods as previously described in adults pa-
tients after HSCT [18,31]. However, analysis of CD3 and ab T
cell recovery after HSCT did not support the hypothesis that
lymphopenia was the driving force for gd T cell peripheral
expansion. Patients with elevated gd T cells did not have
signiﬁcantly lower CD3 or ab T cells, although associations
with NK and B cells were not thoroughly investigated.
Furthermore, some patients in the study received antibodies
directed toward lymphocytes such as ATG or Muromonab-
CD3 (OKT3), although univariate and multivariate analyses
did not ﬁnd signiﬁcant association with gd T cell recovery
after HSCT. A prospective study that provides informationregarding gd T cell reconstitution along with other immune
parameters in a homogeneous population is needed to pro-
vide further insight on the role of gd T cells after HSCT.
gd T cell reactivity toward a microbial metabolite, (E)-4-
hydroxy-3-methyl-but-2-enyl pyrophosphate, has been
demonstrated and indicates a role in activity toward bacterial
infections [32]. Of note, bacterial infections were not observed
in patients with elevated gd T cells. Increased levels of gd T
cells after HSCT have been attributed to infections [2], but data
demonstrating a direct increase in antigen-speciﬁc gd TCR
have not been shown. Studies monitoring gd TCR diversity
after HSCT and during active infections are currently under-
way to better understand the role of gd T cells. In summary,
our results demonstrate that patients who have an enhanced
gd T cell recovery after HSCT are protected with decreased
incidence of infections and improved survival.
The knownpleiotropic effects ofgd Tcells suggestmultiple
mechanisms by which gd T cells may promote survival after
HSCT in pediatric populations. Data suggest that gd T cells
have direct antitumor function in vitro. Godder et al. [17]
showed long-term disease-free survival in mostly adult pa-
tients with elevated gd T cells and suggested a graft-versus-
leukemia effect as a possible mechanism. Although there
were fewer relapses in patients with elevated gd T cells
comparedwithpatientswith low/normalgd Tcells, especially
early after HSCT, the numbers were not signiﬁcant. In larger
studies, the effect of relapse and OS may be more signiﬁcant.
In our study, the protective effect against infection during the
early post-HSCT period was the strongest correlate observed.
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